The Food and Drug Administration approved Pretomanid Tablets, when used alongside 2 other antibiotics, to treat an extremely drug-resistant strain of tuberculosis.
About:
The new drug - Pretomanid - cured 89% of 107 patients with extensively drug-resistant TB after 6 months, when used in combination with antibiotics bedaquiline and linezolid.
The three-drug regimen consists of bedaquiline, pretomanid and linezolid — collectively known as the BPaL regimen.
Significance:
Before the FDA approved this combination therapy, the most common treatment for this type of tuberculosis required patients to take around 30 pills a day plus sometimes daily injections for at least 18 months.
This new treatment lowers that dose to 5 pills/day over 6 months for most patients.
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
